Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TC(r)) hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, two patients for whom previous therapies had failed exhibited virologic break...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discotto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., Colonno, R. J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2004
Témata:
Antiviral Agents
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC514758/
https://ncbi.nlm.nih.gov/pubmed/15328117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.9.3498-3507.2004
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky